• December 12, 2012 (ENG)
    Zymenex in Phase 3 clinical trial in patients with the rare disease alpha-Mannosidosis
  • January 20, 2012 (ENG)
    Zymenex enzyme moves into Phase 2b clinical trials in patients with the rare disease alpha-Mannosidosis
  • December 19, 2011 (ENG)
    Zymenex enzyme gets US Orphan Drug Designation Approval from FDA
  • December 19, 2011 (DK)
    Zymenex enzym opnår US Orphan Drug Designation godkendelse fra FDA
  • October 17, 2011 (ENG)
    Positive clinical effect in Phase 2 trial in patients with the rare disease alpha-Mannosidosis
  • October 17, 2011 (DK)
    Positiv klinisk effekt i fase 2 forsøg i patienter med alfa-Mannosidosis
  • October 3, 2011 (ENG)
    Zymenex enzyme gets EU Orphan Drug Approval
  • October 3, 2011 (DK)
    Zymenex enzym opnår EU Orphan Drug godkendelse
  • January 25, 2011 (ENG)
    Zymenex enzyme in Phase 2 clinical trials in patients with the rare disease alpha-Mannosidosis
  • Januar 25, 2011 (DK)
    Zymenex enzym i fase 2 klinisk forsøg i patienter med den sjældne sygdom alfa-Mannosidosis
  • December 6, 2010 (ENG)
    Zymenex enzyme gets EU-millions for clinical trials in ALPHA-MAN project
  • December 6, 2010 (DK)
    EU-millioner til kliniske studier med Zymenex-enzym
  • September 1, 2010
    Zymenex transfers Krabbe to ACE
  • November 09, 2009
    Zymenex acquires ACE Biosciences
  • May 6, 2008
    Zymenex hosts European Alpha-mannosidosis Disease Group meeting
  • April 24, 2008 (ENG)
    Zymenex sells clinical candidate Metazym to Shire for 135 MUSD
  • April 24, 2008 (DK)
    Zymenex sælger lægemiddelprojekt til Shire for 135 MUSD
  • April 15, 2008
    Zymenex gets US Orphan Approval
  • March 2008
    Zymenex gets FDA approval of IND
  • July 2007
    Novel Natural History Study to answer question in Rare Disease
  • June 2007
    Phase II trial for Zymenex lethal disease treatment candidate
  • May 2007
    Zymenex in Phase I/II clinical trial in seriously ill children with MLD
  • December 2004
    Zymenex strengthens its Board of Directors and positions the company for growth in novel hospital-based therapeutics.
  • June 2004
    Danish Venture Investors BankInvest and Vækstfonden have converted loans of €17.5 million into equity.
  • December 2002
    First study on humans successfully completed.
  • October 2002
    Zymenex gains exclusive access to the US.
  • November 2001
    The Danish/Swedish company Zymenex A/S has received approval to initiate clinical trials for the company’s first product.
Zymenex A/S Roskildevej 12 C
3400 Hillerød, DK		 Tel  +45 48250054
Fax  +45 48251054		 Affiliate Sweden Dalénum 13
181 70 Lidingö, S		 Tel  +46 8 7670203
Fax  +46 8 7670233
© 2004 Zymenex A/S